Dr Kyoichi Kaira
Gunma University Hospital
Nowadays, neoadjuvant chemoimmunotherapy is identified as one of perioperative treatment in early stage non-small cell lung cancer (NSCLC). After 3 cycles of platinum-based regimen plus nivolumab administration, the pathological complete response (p-CR) of 24% was observed, compared to 2.2% in chemotherapy alone. However, there was no established biomarker for predicting the p-CR of chemoimmunotherapy. A exploratory investigation suggested the potential of cfDNA as predictor, however, approximately 75% patients had no detection of cfDNA before chemoimmunotherapy administration. Therefore, it is needed to elucidate the presence of some biomarkers for predicting the p-CR or major pathological response (MPR) at early phase after neoadjuvant chemoimmunotherapy initiation in NSCLC. This special issue focus on the predictive biomarkers of neoadjuvant chemoimmunotherapy.
Submission deadline: 15/09/2024